



U.S. Agent Designation for Service of Process

ATTENTION: Federal Communications Commission
Authorization and Evaluation Division
7435 Oakland Mills Road
Columbia, MD 21046 USA

REGARDING: FCC Certification – Section 2.911(d)(7) Information

Designated U.S. Agent

Company Name: . LIGHT-MED (USA), INC

Contact Name: Gary Lee

Street Address: 1130 Calle Cordillera, San Clemente, CA 92673

City/Province/Zip: San Clemente CALIFORNIA 92673 United States

Telephone No: (949) 218-9555

Email: regulatory@lightmed.com

FRN #: 0036254167

This letter is to confirm that we ("the Designated U.S. Agent) have accepted the responsibility to act as the Designated U.S. Agent for Service of Process as required by section 47 CFR 2.911(d)(7) on behalf of the **Applicant** noted below.

U.S. Agent Signature:

Date: November 20, 2024

Signed by (Printed Name/Title): Gary Lee/ CEO

***This letter is valid indefinitely for all applications submitted within the period of
11/20/2024 – 11/20/2025**

.....

The Applicant confirms its explicit consent and acknowledges that they must maintain an agent for no less than one year after terminating all marketing and importation OR the conclusion of any Commission-related proceeding involving the equipment. The applicant further acknowledges their responsibility to inform the FCC whenever the Designated U.S. Agent information above changes.

Applicant

Company name: LIGHTMED CORPORATION

Grantee Code: 2BH2T

FCC ID: 2BH2T-LCA903R

Contact Name: David Chang

Street Address: No. 1-1, Ln. 1, Sec. 3, Bao'an St., Shulin Dist.

City/Province/Zip: New Taipei City/Taiwan

Telephone No: +886 2 2688 1726

Email: RD@lightmed.com

Applicant Signature:

Date: November 20, 2024

Signed by (Printed Name/Title): David Chang / RD



Certification designating a U.S. Agent for service of process:

As required by section 2.911(d)(7), the applicant must designate a contact located in the United States for purposes of acting as the applicant's agent for service of process, regardless of whether the applicant is a domestic or foreign entity. An applicant located in the United States may designate itself as the agent for service of process.

In either scenario, the designation of the U.S. agent for service of process should be provided as an attachment to the equipment authorization application. The applicant must provide a written certification, which must:

- i. Be signed by both the applicant and designated agent for service of process, if the agent is different from the applicant.
- ii. Acknowledge the applicant's consent and the designated agent's obligation to accept service of process.
- iii. Provide a physical U.S. address and email for the designated agent.
- iv. Acknowledge the applicant's acceptance to maintain an agent for no less than one year after the grantee has terminated all marketing and importation or the conclusion of any Commission-related proceeding involving the equipment.

Unofficial information provided by FCC personnel on February 14, 2023, via the monthly call with the TCB Council:

The Agent for Process of Service:

- cannot be a TCB or affiliated with a TCB (e.g. could not be a person who works for a TCB or a company that owns or is owned by the TCB)
- cannot be a [FCC recognised] Lab or affiliated with a test lab (e.g. could not be a person who works for a Lab or a company that owns or is owned by the Lab)
- Agent can be Individual Entity or a Company Entity
- Agent Entity must be located in US, US address/phone
- Entity acting as Agent must have FRN (best practice, put FRN on Agent Letter)
- Agent letter does not have to be FCC ID specific, can be general Agent for Grantee

For devices being marketed or for which marketing has ceased for less than 1 year, if the Agent for Process of Service changes, then for every TC Number the TCB must request the FCC to put application into Audit Mode and Agent Letter needs to be updated (superseded).

NOTE: The U.S. Agent for Service of Process should not be confused with the authorized agent used for signing the 731 form, other cover letters within the application, and/or the agent who may interface with the TCB.